Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
ConditionType 1 Diabetes
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAugusta University
About this trial
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
Eligibility criteria
Qualifiers
Men and premenopausal women
All races
Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)
Disqualifiers
Clinical diagnosis of hepatic, cardiovascular, or renal disease
Uncontrolled diabetes (HbA1C >12%)
Diabetic complications (i.e. neuropathy)
Uncontrolled hypertension (>140/90 mm Hg on therapy)
Trial design
Treatments tested in this trial
- Resveratrol
- Placebo
Treatment groups
24 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov